BIOEDGE

Biological EDGE

Buy Now

“Meticulous research. Penetrating analysis. A solid framework for change.”  — Dr. Michael J. Krentz

Biological EDGE

Biohacking Starts With NO

Buy Now

“I used to override my body. Now I listen. The difference is stunning.”— Michael Broder

Biohacking Starts With NO
Genetics & Epigenetics

Genetics & Epigenetics Library

Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.

AllLibraryArticlesPresentationsSpotlightsNews

Showing 73–85 of 85

Wiley Aging CellMar 31, 2026

A Cluster of Three snoRNAs Including Jouvence Required in the Gut Determines Lifespan and Confers Neuroprotection Through Metabolic Parameters

A cluster of three small nucleolar RNAs in the gut epithelium regulates lipid and sterol metabolism, with direct effects on lifespan and neuroprotection in aging. Disruption of these snoRNAs causes metabolic dysregulation that leads to neurodegeneration, while restoration in gut cells alone is sufficient to reverse these effects.

Nature - npj AgingApr 3, 2026

Imaging-derived biological age across multiple organs links to mortality and aging-related health outcomes

Imaging-derived biological age—a measure of structural aging across multiple organs—independently predicts mortality and age-related disease risk beyond chronological age. This multi-organ assessment reveals that heterogeneous aging patterns across tissues provide clinically actionable information for longevity planning and intervention timing.

LT WireApr 8, 2026

Alzheon doses first subject in Phase 1 of ALZ-507

Alzheon has initiated Phase 1 trials of ALZ-507, an oral small molecule designed to inhibit neurotoxic amyloid oligomer formation and correct APOE4 dysfunction. The compound demonstrates favorable preclinical safety and pharmacokinetic profiles supporting once-daily dosing, with Phase 2 studies planned across Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy.

Longevity.TechnologyMar 24, 2026

Basecamp Research’s new gene atlas could speed longevity R&D

Basecamp Research's Trillion Gene Atlas expands genetic reference data 100-fold across 100 million species to improve AI drug discovery models for aging. The underlying premise is that current AI systems underperform not due to model limitations but because they train on narrow, repetitive biological data insufficient for solving complex, multisystem conditions like aging.

Wiley Aging CellApr 10, 2026

Human cGAS Drives LINE‐1 Transcriptional Activation to Trigger MAVS‐Dependent Cellular Senescence

Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.

Wiley Aging CellApr 17, 2026

Zfp462 Is a Key Mediator of Osteoblast Differentiation and Might Contribute to Age‐Related Bone Loss

Zfp462 is a transcriptional regulator essential for osteoblast differentiation and bone formation; aging reduces its expression through altered histone occupancy at its locus, providing a mechanistic explanation for age-related bone loss. Restoring Zfp462 activity or its associated transcriptional machinery represents a potential intervention pathway for senile osteoporosis.

Wiley Aging CellMay 11, 2026

FAM162A Is a Key Regulator of Mitochondrial Structure, Dynamics, and Bioenergetics, Driving Cellular Protection and Longevity

FAM162A, a mitochondrial cristae protein, regulates mitochondrial structure and energy production through interaction with OPA1, enhancing cellular stress resistance and extending lifespan in model organisms. This identifies a previously unrecognized mechanism linking mitochondrial dynamics to organismal longevity.

Longevity.TechnologyApr 13, 2026

Alzheon pushes oral Alzheimer’s pipeline forward

Alzheon has dosed the first healthy volunteers in a Phase 1 trial of ALZ-507, an oral Alzheimer's candidate designed to prevent amyloid clumping and correct APOE4 dysfunction. The drug represents a shift toward earlier intervention and simplified delivery in a disease where accessibility and tolerability have historically limited treatment adoption.

Longevity.TechnologyMar 16, 2026

Biotech lands $45m to drug the undruggable

Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.

Longevity.TechnologyFeb 10, 2026

Half of how long we live might be in our genes

A twin-based study published in Science estimates genetic influence accounts for approximately 55% of human lifespan variation, with the remaining 45% shaped by diet, exercise, habits, and environmental factors. This finding reframes longevity as neither purely genetic nor purely behavioral, but rather a composite outcome where lifestyle interventions remain substantively meaningful within genetically-established boundaries.

Nature AgingMar 6, 2026

Mining the prodrome of neurodegeneration

Transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease, each with unique clinical trajectories, comorbidities, and genetic profiles. This stratification approach enables more precise disease understanding and potentially more targeted intervention strategies across the neurodegenerative disease landscape.

LifeSpan.ioFeb 6, 2026

First Human Cellular Reprogramming Trial Cleared by the FDA

Life Biosciences has received FDA clearance to begin the first human trial of cellular reprogramming, testing ER-100 against age-related vision diseases. This represents the first clinical translation of partial reprogramming technology, moving a three-decade research program from laboratory validation into human application.

Wiley Aging CellMay 6, 2026

Estimating Vascular Age to Evaluate the Association Between Aging and Cardiovascular Disease

Vascular age acceleration, measured through a quantitative model, independently predicts cardiovascular disease risk beyond chronological age, with a 21–25% increased risk in those showing accelerated vascular aging. This metric enables earlier identification of individuals requiring intervention before overt disease manifestation.